74 results about "ELAV Proteins" patented technology

Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.

The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX, utilizing an immortalized human cell line stably expressing viral transcription activator proteins and carrying a vector having a promoter functionally linked to a DNA sequence coding for a blood coagulating factor, provided that said promoter is not a viral promoter which is stimulated by said viral transcription activator proteins; an immortalized human cell line carrying said vector, factor VIII muteins particularly suitable for the above production method; pharmaceutical compositions comprising such factor VIII muteins and the use of such factor VIII muteins for preparing a medicament for treating hemophilia.

The invention provides a helicobacter pylori tetravalent virulence factor multi-epitope vaccine and a preparation method thereof. The active constituent of the vaccine is polypeptide. The vaccine mainly comprises the dominant Th and B cell epitopes or sections of a urease A subunit, a urease B subunit, cytotoxin associated protein A and vacuolating cytotoxin associated protein A, and neutrophil activating protein. The gene synthesis and molecular cloning technology is used for building a fused gene containing the dominant Th and B cell epitopes or sections of ureases, the cytotoxin associated protein A and the vacuolating cytotoxin associated protein A, and the neutrophil activating protein. Escherichia coli is used for expressing the fused gene, and the tetravalent virulence factor multi-epitope vaccine is obtained after protein purification. The vaccine can stimulate a body to generate T cell immunity response and specific antibody humoral immunity response aiming at the ureases, the cytotoxin associated protein A, the vacuolating cytotoxin associated protein A and the neutrophil activating protein and can be used for preventing and treating diseases related to helicobacter pylori infection.

In accordance with the present invention, there are provided selection systems and methods for screening for agents that control splicing of inteins in their native host protein (extein) or in homologous exteins. Specifically, there are provided positive genetic selection systems for the screening of agents which inhibit or activate protein splicing which comprise: a host cell containing a chromosomal gene encoding either a drug-resistant form of a target enzyme or a wild-type target enzyme, and a plasmid-borne gene encoding either a drug-sensitive form of the target enzyme, which is dominantly cytotoxic upon interaction with the drug, or a dominantly cytotoxic form of the target enzyme. In these systems the plasmid-borne gene contains an intein, and the inhibition or activation of splicing of the dominant cytotoxic form of the target enzyme by a given reagent results in the survival or death of the host cell. More specifically, positive genetic selection systems which utilize the M. xenopi GyrA intein or M. tuberculosis DnaB helicase intein are provided. Similar reporter systems utilizing native or homologous exteins and systems utilizing controllable inteins are provided, as are methods of controlling in vivo expression of proteins by modulating protein splicing with inhibiting or activating agents, and methods of controlling the delivery of proteinaceous drugs in vivo by modulating protein splicing.

A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).

The invention discloses an application of oridonin in preparing an activator of tumor-suppressor protein FBW7 (F-box and WD repeat domain containing 7). According to a large number of studies, oridonin can activate the expression of FBW7 protein and enhance the affinity of FBW7 protein to a substrate protein, so that FBW7-medicated ubiquitination degradation pathway is rapidly and efficiently activated. Oridonin target-degrades cancer protein such as c-Myc, cyclinE and mTOR through activation of the FBW7-medicated ubiquitination degradation pathway, so as to inhibit the growth of a variety oftumor cells and induce cell apoptosis. Oridonin is mainly derived from traditional Chinese medical material Rabdosia rubescens, is easy to prepared, has low toxicity to human body, and has high applicability.

The invention discloses a CRISPR-Cas13 nucleic acid detection kit based on a lightening type RNA aptamer. The kit comprises the lightening type RNA aptamer, Cas13 protein, crRNA and nucleic acid dye; the lightening type RNA aptamer can be combined with nucleic acid dye to emit fluorescence, and if the lightening type RNA aptamer is sheared by Cas13 protein, fluorescence is quenched; the crRNA is a section of RNA, the crRNA and Cas13 protein can form a crRNA-Cas13 compound, and after the Cas 13-crRNA is combined with a target RNA sequence, the enzyme digestion activity of the Cas13 protein is activated, and an RNA aptamer is excised. The kit can detect living pathogens and RNA markers by detecting RNA, and compared with an existing nucleic acid detection method based on CRISPR-Cas13, the method does not depend on reverse transcription and nucleic acid amplification, target RNA sequence detection is completed in one step, the detection cost is low, the operation steps are simple, high specificity and sensitivity can be guaranteed, and industrial application is facilitated.

The invention relates to a novel application of gamma-secretase activated protein gene and/or protein coded by gamma-secretase activated protein gene. According to the application disclosed by the invention, by screening acute myelogenous leukemia (AML) prognosis related molecular markers, the screened gamma-secretase activated protein gene (GSAP) is closely related to the prognosis of acute myelogenous leukemia patients; the high expression of the GSAP prompts that the prognosis of the acute myelogenous leukemia patient is poor; the GSAP is related to FAB typing and cytogenetics risk stratification of an acute myelogenous leukemia patient; and the GSAP may participate in the disease progress of acute myelogenous leukemia through various ways such as PI3K-AKT, TLR and the like. The GSAP is used for preparing a treatment drug or a diagnostic reagent and a prognosis detection reagent for acute myelogenous leukemia.

The invention discloses an application of NRF2 protein in preparation of a drug for regulating biorhythm. An NRF2 agonist is bortezomib. The application has the beneficial effects that rapid adjustment and no-interference adjustment of the biorhythm can be realized; specifically, the application is implemented in that 1) the NRF2 protein is directly activated, so that the NRF2 rapidly enters a cell nucleus to play a role, so that a slow-speed adjustment path by increasing the content of the NRF2 protein in a DNA-mRNA-protein process is avoided; and 2) the content of the biorhythm protein is directly increased by promoting the combination of the NRF2 protein and a biorhythm related gene, so that the biorhythm is rapidly adjusted, a slow-speed adjustment path by increasing the content of thebiorhythm content indirectly through a biorhythm feedback protein is avoided, and the interference of the biorhythm feedback protein on the biorhythm protein content is also avoided.

The invention relates to application of peptide vaccines and microgene vaccines based on CTL epitope peptides of FAPalpha, and belongs to the field of tumor peptide vaccines and DNA vaccines with fibroblast activator protein alpha as a target. The invention discloses an FAPalpha derived antitumor epitope peptide FAP.291 and a mimic peptide FAP.291I9 of the FAPalpha derived antitumor epitope peptide FAP.291 and application of microgene DNA vaccines constructed by the FAPalpha derived antitumor epitope peptide FAP.291 and the mimic peptide FAP.291I9 of the FAPalpha derived antitumor epitope peptide FAP.291 in preparation of tumor therapeutic vaccines. Through screening and identification, the epitope FAP.291 and the mimic epitope FAP.291I9 are determined, so that a specific CTL reaction in BALB/c mice can be effectively activated. The invention further relates to application of the vaccines using FAP.291 and FAP.291I9 small peptides in combination with adjuvants and constructing microgene forms of the FAP.291 and FAP.291I9 small peptides in tumor prevention.

The invention relates to a urate oxidase with catalytic activity. A 'resurrection' human urate oxidase amino acid sequence with catalytic activity, a nucleotide sequence for encoding the protein, a vector containing the nucleotide sequence and a host cell containing the vector are obtained by adopting genetic engineering technology modification. The invention also discloses a method for preparing the resurrection protein by using a genetic engineering technology, and a product obtained by modifying the protein. The urate oxidase has good enzymatic activity and stability, the coding sequence of the urate oxidase maintains high homology with human urate oxidase pseudogenes, and the urate oxidase has good prospects in preparation of low-immunogenicity or even immunogenicity-free uric acid lowering drugs or pharmaceutical compositions.

The invention discloses a plant immune activator protein PlAvh23 secreted by peronophythora litchii and an application of the plant immune activator protein PlAvh23. A novel peronophythora litchii RXLR type effect protein PlAvh23 is identified, and the amino acid sequence of the novel peronophythora litchii RXLR type effect protein PlAvh23 is selected from any one of the following sequences: (a) an amino acid sequence as shown in SEQ ID NO: 1; (b) an amino acid sequence as shown in SEQ ID NO: 4; and (c) an amino acid sequence as shown in SEQ ID NO: 6. The plant immune activator protein PlAvh23 can induce plants to generate immune response, reduces infection of pathogenic bacteria, provides a new way for improving plant resistance, and can be applied to prevention and treatment of litchi downy blight.

This disclosure relates to the field of high scale production of recombinant Adeno-Associated Viruses (AAVs). The inventors have conceived of specific nucleic acid constructs that allow for high scale production of recombinant AAV particles in insect cells. Importantly, these nucleic constructs do not require the production of a heterologous AAP. This disclosure thus relates to a nucleic acid for producing AAV capsids in insect cells, where the nucleic acid includes a first open reading frame encoding the VP1, VP2, and VP3 proteins, and a second open reading frame encoding the Assembly-Activating Protein (AAP).

The invention discloses a monoclonal antibody capable of specifically recognizing activation of Galphaz protein and a preparation method thereof, belonging to the field of bioscience and medicine development. The monoclonal antibody is generated by hybridoma which is collected in China Center for Type Culture Collection (CCTCC), and the collection number is CCTCC NO: C2010109. The monoclonal antibody prepared by the method can specifically recognize the activation state of Galphaz protein.

The present invention relates to agents enhancing HuR/ELAV levels for use in the treatment of BRAF-mutated cancers and uses thereof. In particular, the invention relates to the use of agents enhancing HuR/ELAV levels in combination with BRAF inhibitors for the treatment of BRAF-mutated cancers, in particular melanoma and to methods for identifying agents useful for potentiating the effects of BRAF inhibitors, when used in combination.